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abstract
PURPOSE Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost importance.
On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 weeks administration of
high-dose sunitinib in patients with refractory solid malignancies was conducted.
PATIENTS AND METHODS Patients with advanced cancer refractory to standard treatment were eligible. With use
of a standard 3 + 3 phase I design, patients received escalating doses of sunitinib, in 100 mg increments,
starting at 200 mg once weekly. In both the once weekly and once every 2 weeks cohorts, 10 more patients were
included at the maximum tolerated dose level. Primary end points were safety and tolerability.
RESULTS Sixty-nine patients with advanced cancer, predominantly colorectal cancer (42%), were treated with
this alternative dosing regimen. Maximum tolerated dose was established at 300 mg once weekly and 700 mg
once every 2 weeks, resulting in nine- and 18-fold higher maximum plasma concentrations compared with
standard dose, respectively. Treatment was well tolerated, with fatigue (81%), nausea (48%), and anorexia
(33%) being the most frequent adverse events. The only grade 3 or 4 treatment-related adverse event in 5% or
more of patients was fatigue (6%). Sixty-three percent of patients had significant clinical benefit, with a 30%
progression-free survival of 5 months or more.
CONCLUSION Sunitinib administered once weekly at 300 mg or once every 2 weeks at 700 mg is feasible, with
comparable tolerability as daily administration. Administration of 700 mg once every 2 weeks can be considered
as the most optimal schedule because of the highest maximum plasma concentration being reached. The
promising preliminary antitumor activity of this alternative schedule in heavily pretreated patients warrants
further clinical evaluation and might ultimately indicate a class characteristic of tyrosine kinase inhibitors.
J Clin Oncol 37:411-418. © 2018 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Treatment with tyrosine kinase inhibitors (TKIs) often
results in durable clinical responses and survival benefit
with an acceptable safety profile for patients with ad-
vanced malignancies.1 Nonetheless, resistance to TKIs
eventually develops in all patients. The current use of
TKIs is based on the principle that prolonged drug
exposure is necessary for optimal antitumor activity
because of continuous inhibition of angiogenesis and
specific intracellular signaling.2 However, the occur-
rence of toxicity leads to a narrow therapeutic window,
which impedes additional dose escalation and drug
exposure.3 It is hypothesized that the clinical efficacy of
these agents might be further improved by optimization
of treatment schedules and dosing.4 Disease progres-
sion has been attributed to subtherapeutic levels,
whereas dose escalation might overcome the initial
development of resistance,5 and increased exposure
correlates with improvement in clinical benefit.6
Sunitinib malate (SUTENT; Pfizer, New York, NY) is an
orally administered TKI that targets multiple kinase
receptors, including the vascular endothelial growth
factor (VEGF) receptor and platelet-derived growth
factor receptor. It is approved for patients with renal
cell cancer, GI stromal cell tumors (GISTs), or pan-
creatic neuroendocrine tumors in a dose of 50 mg per
day for 4 weeks followed by a 2-week off period or a
continuous regimen of 37.5 mg doses per day.7
Clinical feasibility and safety of higher sunitinib doses
were previously reported when a single dose of
sunitinib up to 300 mg was safely administered to
patients.8 We hypothesized that intermittent, high-
dose administration of sunitinib might ultimately re-
sult in higher plasma and subsequent intratumoral
concentrations, leading to enhanced efficacy. We have
previously demonstrated that short exposure to high
concentrations of sunitinib leads to complete inhibition of
tumor cell proliferation in vitro and significantly impairs
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tumor growth in vivo compared with continuous lower ex-
posure.9 Other scientific support for the role of TKI dose
escalation comes from a meta-analysis that indicated the
proportional relationship between drug exposure and the
probability of response.6 Recently, intrapatient dose escalation
at the time of progression in patients who were receiving
sunitinib was shown to overcome resistance, although tran-
siently, and resulted in an increase in progression-free survival
of greater than or equal to 5 months.5
Identification of optimal treatment strategies is actively
pursued for other TKIs. Comparable to our study with
sunitinib, weekly 10-fold–higher doses of erlotinib have
been reported as salvage therapy in patients with non–
small-cell lung cancer and leptomeningeal metastases with
an acceptable toxicity profile.10 Imatinib dose escalation
has been suggested as an effective therapy for advanced
GIST after progression on standard dose in patients who
harbor exon 9 mutations, which underscores the need for
dose individualization.11 Almost all patients with imatinib-
resistant metastatic GIST eventually develop resistance to
treatment with sunitinib, generally within 1 year, which
results in disease progression.12 Mechanisms of GIST re-
sistance to sunitinib treatment are largely unknown.13
Because sunitinib targets a broader spectrum of kinases
compared with imatinib, additional mechanisms possibly
play a role in the acquisition of resistance. The promising
antitumor activity of this high-dose sunitinib strategy po-
tentially could overcome therapy resistance to sunitinib in
these patients similar to those observed with imatinib.14 On
the basis of these preclinical and clinical findings, the
current phase I clinical trial was conducted to investigate
the maximum tolerated dose (MTD) of once weekly or once
every 2 weeks administration of sunitinib, the safety and
clinical feasibility, the pharmacokinetic parameters, and
the preliminary efficacy in patients with advanced solid
malignancies refractory to standard treatment.
PATIENTS AND METHODS
Patient Eligibility
Eligible patients included adults with histologically con-
firmed advanced solid tumors that were progressive after
standard treatment. Major inclusion and exclusion criteria
are listed in the Data Supplement. The study was con-
ducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines. Before inclusion, pa-
tients provided informed consent on the study protocol
approved by the local institutional review board.
Study Design and Treatment Plan
This dose escalation, phase I, single-institution clinical trial
was conducted at the Vrije Universiteit Medical Center,
Amsterdam, the Netherlands. A standard 3 + 3 design was
used with a starting dose cohort of 200 mg sunitinib ad-
ministered orally once weekly and escalating in increments
of 100 mg. Patients continued sunitinib until progression,
intolerance, or consent withdrawal. The primary objective
was to determine the MTD and evaluate the safety and
tolerability, whereas secondary objectives were to assess
the pharmacokinetic parameters of this scheduling and
preliminary assessment of the efficacy of sunitinib in-
termittent treatment. Once weekly MTD level was sub-
sequently set as the starting dose level for the once every
2 weeks schedule, which followed the same design prin-
ciples. Patients were considered evaluable (for toxicity,
pharmacokinetics, and response) who completed a mini-
mum of 2 weeks of sunitinib treatment, which means two
administrations of sunitinib on the once weekly schedule
and one administration of sunitinib in the once every
2 weeks schedule, including 2 weeks of follow-up. After
determination of the MTD, both schedules expanded to
include 10 additional patients at the MTD level to evaluate
preliminary efficacy.
Safety Assessment
Physical condition assessments, including ECG and blood
hematology and chemistry, were performed weekly during
the first 8 weeks and once every 4 weeks thereafter. Ad-
verse events (AEs) were monitored throughout the study
and graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events (version
4.0). MTD was defined as the highest dose level at which
less than or equal to 33% of patients experienced dose-
limiting toxicities (DLTs). DLT was defined as any grade 3 or
higher toxicity attributable to sunitinib that occurred during
the first 6 weeks of therapy.
Pharmacokinetics
Blood samples for pharmacokinetic assessments were
collected pretreatment and subsequently at multiple time
points (0, 2, 4, 6, 8, 10, and 24 hours postdose on day 1 for
both time schedules and thereafter at days 3, 8, 10, 15, 17,
and 22 for the once weekly schedule and at days 3, 15, 17,
and 29 for the once every 2 weeks schedule). Sunitinib
plasma concentrations were determined by liquid
chromatography-mass spectrometry.15 To evaluate suniti-
nib exposure, peak concentration, half-life, area under the
concentration-time curve, and time to half-life were cal-
culated with the validated PKSolver add-in for Microsoft
Excel 2010 (Microsoft Corporation, Redmond, WA).
Treatment Efficacy
All patients underwent computed tomography scanning at
baseline and subsequently every 8 weeks for evaluation of
efficacy. Antitumor response was evaluated by Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
PFS was defined as the time from the date of the first dose
of study medication to the date of first disease progression
or the date of death.
Statistical Analysis
Descriptive statistics were used for baseline characteristics,
safety assessment, and pharmacokinetic data. Data are
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expressed as mean 6 standard deviation when
appropriate.
RESULTS
Patients
A total of 73 patients had been included in the study of
whom 71 started study medication and 69 received
sunitinib for 2 weeks or more. The baseline patient char-
acteristics are listed in Table 1. Median age was 62 years
(range, 29 to 85 years), and 64 patients (88%) had a WHO
performance status of 1. Colorectal cancer (CRC) was the
most frequent tumor type (42%). All patients were pre-
treated extensively, with 67% having received two or more
previous treatment lines. The reason for not starting study
medication for two patients after enrollment was rapid
deterioration in clinical status. In the escalation cohorts, 12
patients at the MTD (six in the 300 mg once weekly cohort
and six in the 700 mg once every 2 weeks cohort) received
(at least) every dose that was scheduled in the first 6 weeks
of therapy (DLT window). In the expansion cohort, another
20 patients (10 in each cohort) received at least 6 weeks of
sunitinib treatment.
Safety
High-dose, intermittent sunitinib demonstrated a toxicity
profile comparable to the standard flat dose. Table 2 lists all
clinically significant toxicities that occurred in 10% or more
of the 69 patients evaluable for toxicity (grade 1 or 2) and all
grade 3 or 4 treatment-related AEs. The most commonly
observed AEs of any grade were fatigue (n = 56; 81%),
nausea (n = 33; 81%), and anorexia (n = 23; 33%). With
regard to grade 3 or higher AEs, four patients (6%) ex-
perienced grade 3 fatigue. The majority of adverse effects
were constitutional and manageable with standard sup-
portive care interventions. Severe bowel toxicity (presacral
abscess) was observed in one patient who received the first
dose level (200 mg) in the once weekly cohort (outside the
DLT period), whereas one patient who received the third
dose level (400 mg once weekly) presented with a fatal
bowel perforation (during the DLT period). Both patients
had been irradiated previously in the affected area. These
serious AEs led to an amendment of the study protocol to
exclude patients with a history of pelvic, thoracic, and
extended vertebral irradiation. After the amendment, at the
dose level of 400 mg once weekly, DLTs occurred in two
patients: One developed grade 3 bile stasis, and one de-
veloped grade 3 fatigue. One patient on the 400 mg once
weekly schedule and with CRC and extensive peritoneal
carcinomatosis with a substantial clinical benefit lasting
longer than 7 months developed a bowel perforation at the
time of disease progression as a result of a growing peri-
toneal tumor lesion. He underwent a successful operation.
The dose level of 300 mg weekly was expanded to six
patients and no additional DLTs were observed. Therefore,
the MTD was determined at 300 mg once weekly.
Subsequently, enrollment in the once every 2 weeks
schedule was initiated at the MTD level of the once weekly
schedule, that is, 300 mg once every 2 weeks, and es-
calated in steps of 100 mg. Because patients experienced
no DLTs, doses were escalated up to 800 mg once every
2 weeks in subsequent cohorts. In the 800-mg cohort, two
patients experienced a DLT: One developed a combination
of a grade 3 increase in ALT and AST, and one developed a
grade 3 hepatobiliary disorder (bile duct obstruction). The
MTD of the administration of sunitinib once every 2 weeks
was set at 700 mg. Dose escalation steps and DLTs are
listed in Appendix Table A1 (online only).
Pharmacokinetics
Pharmacokinetic parameters of sunitinib16 are listed and
compared with standard scheduling in Table 3. Exposure to
sunitinib, as designated by an increase in the maximum
plasma concentration (Cmax), increased across dose levels
(0.1676 0.06, 0.2616 0.12, and 0.2196 0.07 mg/mL for
the 200-, 300-, and 400-mg dose levels once weekly, re-
spectively, and 0.2156 0.12, 0.4006 0.12, 0.3016 0.16,
TABLE 1. Patient Demographics and Clinical Characteristics
Characteristic Patients, No. (%)
No. registered 73
Median age, years (range) 62 (29-85)
Sex
Male 37 (51)
Female 36 (49)
ECOG performance status
0 9 (12)
1 64 (88)
Median prior treatment lines (range) 2 (0-9)
Tumor type
Colorectal cancer 31 (42)
Cholangiocarcinoma 7 (10)
Breast cancer 6 (8)
Neuroendocrine carcinoma 6 (8)
Pancreatic cancer 4 (6)
Hepatocellular carcinoma 4 (6)
Head and neck cancer 3 (4)
Ovarian cancer 3 (4)
Adrenal carcinoma 2 (3)
Esophageal cancer 2 (3)
Glioblastoma multiforme 1 (1)
Parotid gland cancer 1 (1)
Adenocarcinoma of unknown primary 1 (1)
Renal cell cancer 1 (1)
Stomach cancer 1 (1)
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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0.3576 0.12, 0.5056 0.15, and 0.5516 0.28 mg/mL for
the 300, 400, 500, 600, 700, and 800 mg dose levels once
every 2 weeks, respectively). Cmax was achieved in ap-
proximately 2 to 8 hours and provided nine to 18 times
higher peak concentrations than standard dosing.16
Although significant interpatient variability was noted,
intrapatient variability was minimal, and almost no plasma
drug accumulation of sunitinib occurred in time. The mean
terminal half-life of sunitinib was approximately 44 hours.
The majority of patients (97%) reached a Cmax higher than
0.1 mg/mL (250 nM). Dose escalation led to a proportionate
increase in drug exposure (Fig 1). Pharmacokinetics of the
metabolite of sunitinib (SU12662) followed the same
pattern of sunitinib itself and are both listed in Appendix
Table A2 (online only).
Treatment Efficacy
Clinical benefit from treatment was characterized by prolonged
disease stabilization, tumormarker response, and improvement
of disease-related symptoms. Of 69 patients, 59 were evaluable
for response. Of the other 10 patients, five presented with a
DLT, two withdrew consent at week 3 for nonmedical reasons,
two stopped because of a non–treatment-related serious AE,
and treatment of one patient was discontinued by the in-
vestigator when the study was put on hold to await for the
amendment. Thirty-seven patients (63%) had clinical benefit
defined as progression free at 2 months of treatment, whereas
30% (18 of 59) had stable disease for 5 months or longer (Fig
2). Mean PFS in theMTD group was 3.5 months (range, 0.5 to
9.2 months). The range for the duration of treatment (all pa-
tients) was 0.5 to 47 weeks. The median duration of therapy
was 8 weeks, and the mean was 14 weeks.
Despite RECIST version 1.1 stable disease on computed
tomography evaluation, on-treatment scans were indicative
of tumor necrosis in most patients with clinical benefit
characterized by homogenous hypo-attenuation and sharp
tumor-liver interface17 (Fig 3). When response evaluation
was based on modified Choi criteria,18 a 32% response rate
was reached for the 59 patients at the time of first
evaluation.
Twenty-seven of all participating patients had detectable
blood tumor markers (eg, carcinoembryonic antigen,
CA15.3, CA19.9 [greater than the upper limit of normal]).
Compared with baseline, the eight patients with the longest
time on treatment (5 months or more PFS) had a significant
tumor marker decrease at first evaluation compared with
baseline (235% 6 22%; P = .02). No tumor marker re-
sponse was seen in the 10 patients who progressed (an
increase of 94 6 124%; P = .2). Almost all patients (96%)
presented with a significant tumor marker increase 24 to
72 hours after first dose ingestion.
DISCUSSION
Treatment strategies with multitargeted TKIs have been
focused on continuous drug exposure at their MTD for
optimal target inhibition.3 This continuous inhibition of
targeted signaling pathways has been proposed as key for
their mechanism of action leading to clinical antitumor
activity.19
Proof of concept for this dogma is lacking mainly because
of the difficulty to measure adequately true inhibition of
TABLE 2. Related Adverse Events
Grade, No. (%; n 5 69)
Adverse Event
1-2 (‡ 10% of
patients)
3 (all
patients)
> 4
(all patients)
Fatigue 52 (75) 4 (6)
Nausea 32 (46) 1 (1)
Anorexia 23 (33)
Skin disorders 18 (26)
Vomiting 17 (25)
Diarrhea 15 (22)
Dysgeusia 15 (22)
Platelet count decreased 14 (20) 2 (3)
Tumor pain 13 (19) 3 (4)
Palmar-plantar erythrodysesthesia
syndrome
13 (19)
ALT increased 12 (17) 1 (1)
AST increased 11 (16) 3 (4)
Mucositis oral 11 (16) 1 (1)
Malaise 11 (16)
Anemia 10 (14) 3 (4)
Fever 9 (13)
Yellow skin 8 (12) 1 (1)
Neutrophil count decreased 8 (12) 2 (3)
Headache 8 (12)
Hypothyroidism 8 (12)
Edema limbs 7 (10)
Hypertension 6 (9) 3 (4)
Constipation 5 (7) 1 (1)
Hypo-albuminemia 4 (6) 1 (1)
Bile duct stenosis 2 (3)
Rectal perforation 1 (1) 1 (1)
Colonic perforation 1 (1)
Skin infection 1 (1)
Esophageal varices hemorrhage 1 (1)
Pneumonia 1 (1)
Rectal hemorrhage 1 (1)
Gait disturbance 1 (1)
Dyspnea 1 (1)
Thromboembolic event 1 (1)
NOTE. Nausea and anorexia were seen predominantly on days 1 and 2 of the
new schedule and managed with standard use antiemetics (n = 69).
414 © 2018 by American Society of Clinical Oncology Volume 37, Issue 5
Rovithi et al
Downloaded from ascopubs.org by Radboud University Nijmegen on May 6, 2020 from 131.174.248.182
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
specific drug targets in patient tumor samples. Dissimilarly,
conventional cytotoxic approaches include the adminis-
tration of intense, intermittent doses.20 In this study, we
aimed to reach the highest tolerable peak plasma con-
centrations with the subsequent highest intratumoral peak
concentrations for the drug to exert direct cytocidal effects
and suffice to block targets with a lower drug-binding af-
finity at the tumor level on the basis of preclinical experi-
ments.9 On the basis of this hypothesis, we conclude that
administration of 700 mg of sunitinib once every 2 weeks,
the dose at which the highest Cmax is received, is the
optimal alternative high-dose treatment schedule.
The sunitinib daily dosing strategy was established in the
original first-in-human, phase I study where responses
were reported in five patients.16 Phase III studies of
sunitinib standard dosing, with 4 weeks 50 mg per day
administration followed by 2 weeks treatment in-
terruption, resulted in the approval of sunitinib to treat
patients with metastatic renal cell cancer, imatinib-
resistant GIST, and advanced neuroendocrine pancreatic
TABLE 3. Pharmacokinetic Parameters of Intermittent High-Dose Sunitinib
Dose No. of Patients
Mean Cmax,
mg/mL (SD)
Mean Tmax,
hours (range)
Mean AUC0-48, mg
hour/L (SD)
Mean AUC0-‘ mg
hour/L (SD)
Mean T1/2,
hours (SD)
Once per week, mg
200 3 0.167 (0.06) 6 (4-6) 5.034 (1.8) 19.88 (16.1) 66.1 (9.3)
300 20 0.261 (0.12) 6 (2-10) 7.645 (2.4) 21.49 (11.6) 56.2 (35.4)
400 10 0.219 (0.07) 8 (4-24) 7.156 (2.8) 22.86 (11.1) 71.8 (29.3)
Once every 2 weeks, mg
300 3 0.215 (0.12) 2 (2-6) 4.862 (2.3) 7.088 (3.0) 25.4 (8.6)
400 4 0.400 (0.12) 9 (8-10) 9.208 (2.5) 14.471 (3.3) 27.45 (5.5)
500 3 0.301 (0.16) 8 (6-8) 9.450 (2.6) 18.833 (3.897) 50.5 (32.8)
600 3 0.357 (0.12) 6 (2-8) 6.139 (1.0) 6.736 (1.06) 12.4 (3.4)
700 15 0.505 (0.15) 8 (4-24) 16.125 (6.2) 35.734 (23.73) 45.21 (24.8)
800 7 0.551 (0.28) 8 (6-10) 17.560 (9.7) 36.035 (22.17) 41.64 (10.1)
Once per day 4 on/2 off
schedule, mg
50 0.028 5 0.42 41-86
NOTE. Mean pharmacokinetic parameters after first dose of sunitinib.
Abbreviations: AUC0-48, area under the plasma concentration-time curve from time 0 to 48 hours after dose; AUC(0-‘), area under the plasma
concentration-time curve from time 0 to infinity; Cmax, peak plasma concentration; SD, standard deviation; T1/2, elimination half-life; Tmax, time to maximum
plasma concentration.
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cancers with significant clinical and overall survival
benefit.
In the current phase I clinical trial, sunitinib administration
at a dose of 300 mg once weekly or 700 mg once every
2 weeks was shown to be safe and tolerable with a com-
parable toxicity profile as the standard sunitinib schedule of
50 mg given for 28 days with a 14-day break recently
reported in the Alliance 031203 CABOSUN trial.21 In our
phase I trial, grade 3/4 and 5 AEs related to intermittent
high-dose sunitinib (once weekly or once every 2 weeks)
occurred in 46% and 2% of patients compared with 68%
and 7% of patients treated with the standard sunitinib
schedule in the CABOSUN trial. The most frequently re-
ported grade 3/4 toxicity was fatigue, which occurred in four
(6%) of 69 patients in our phase I trial compared with 11
(15.3%) of 72 patients in the CABOSUN trial. The AEs of
nausea and anorexia were predominantly seen on days 1
and 2 of the new schedule and well manageable with
standard use of antiemetics.
Pharmacokinetic evaluation in our trial clearly indicated
that intermittent high peak concentrations could be
reached without detrimental toxicity because the majority of
the patients reached a Cmax greater than 0.1 mg/mL (250
nM). Patients in the standard scheduling with trough
concentrations of more than 0.1 mg/mL exhibited DLTs.22
We consider these peak concentrations as most likely re-
sponsible for the direct antitumor activity in accordance
with preclinical findings.9
Administration of this alternative scheduling was compli-
cated by the development of serious bowel toxicity in two
patients who both received prior radiotherapy. Radiother-
apy has previously been reported as a contributing factor
to serious bowel toxicity seen with concomitant anti-
angiogenic treatment, including sunitinib specifically.23,24
The underlying mechanisms are still to be elucidated. The
working hypothesis assumes inadequate capability of tis-
sue repair after radiation-induced bowel injury because of
an impaired VEGF response.25 After exclusion of patients
who were previously irradiated at the bowel region, no
additional serious bowel toxicity was observed.
Recently, Chien et al26 translated data from mouse models
in which intermittent high- dose lapatinib resulted in im-
proved efficacy compared with the standard continuous
low- dose therapy. These investigators reported a phase I
trial that investigated this schedule in patients with ad-
vanced solid tumors. High-dose, intermittent lapatinib was
well tolerated and resulted in significantly increased plasma
concentrations. In addition, a relationship between lapa-
tinib exposure and biologic activity was established; pa-
tients with plasma concentrations approximating 10 mg/mL
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FIG 2. Progression-free survival (PFS) for all evaluable patients after
once per week and once every 2 weeks administration of sunitinib.
Baseline First EvaluationA B
FIG 3. Stable disease in a patient with
metastatic colorectal cancer during
treatment. Computed tomography
scans (A) before treatment and (B) at
first evaluation (8 weeks). The on-
treatment scan indicates tumor ne-
crosis characterized by homogeneous
hypo-attenuation and sharp tumor-
liver interface (Data Supplement).
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presented with marked responses, whereas all patients
with low lapatinib plasma concentrations had progressive
disease.26
In this trial, 20% of the evaluable patients with CRC reached
a PFS of more than 5 months (range, 5.5 to 12.5 months),
which is notable because in the original phase I study, none
of the three patients with CRC showed a long-lasting re-
sponse or tumor stabilization.16 In a subsequent phase II
clinical trial, sunitinib was evaluated in the metastatic CRC
setting where 16% of patients with CRC reached a PFS of
5 months or more27 and concluded that daily sunitinib
monotherapy provides no significant clinical benefit;
therefore, further development of sunitinib for CRC was
terminated. Although the only approved TKI for CRC,
regorafenib shows a small, but significant overall survival
benefit with a challenging toxicity profile.28 Our results
indicate that alternative dosing of sunitinib may provide a
promising strategy for the treatment of patients with ad-
vanced CRC with an acceptable toxicity profile.
To determine the efficacy of pulsatile, high-dose sunitinib in
patients with metastatic CRC, we will start shortly a pro-
spective, randomized, open-label, phase II/III clinical trial to
compare 700 mg sunitinib once every 2 weeks with
standard treatment with Trifluridine plus tipiracil (TAS-102)
in patients with metastatic adenocarcinoma of the colon or
rectum who are refractory or intolerant to therapy with
fluorouracil, oxaliplatin, and irinotecan anti-VEGF therapy
(and anti–epidermal growth factor receptor therapy in
KRAS wild type).
In conclusion, pulsatile, high-dose sunitinib was well tol-
erated and exhibited preliminary clinical significant benefit
in patients with refractory solid malignancies, which war-
rants its development. The once every 2 weeks adminis-
tration of 700 mg sunitinib is feasible and the most optimal
schedule because of the highest Cmax being reached. Our
study highlights the importance to improve further the
efficacy of this new class of agents by optimization of dose
and scheduling strategies.
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APPENDIX
TABLE A1. Dose Levels and Dose-Limiting Toxicities (escalating cohorts)
Schedule Dose No. of Patients Dose-Limiting Toxicities
Once weekly, mg
200 3 None
300 6 None
400 6 Grade 4 bowel perforation (n = 1)
Grade 3 bile duct stenosis (n = 1)
Grade 3 fatigue (n = 1)
Once every 2 weeks, mg
300 3 None
400 3 None
500 3 None
600 3 None
700 6 None
800 6 Grade 3 increased AST and ALT (n = 1)
Grade 3 hepatobiliary disorder, cholangitis (n = 1)
TABLE A2. Summary of Measured Pharmacokinetic Parameters of SU12662
Dose No. of Patients Mean Cmax, mg/mL (SD) Mean Tmax, hours (range) Mean T1/2, hours (SD)
Once weekly, mg
200 3 0.025 (0.01) 6 (4-6) 116 (17)
300 14 0.021 (0.01) 6 (2-10) 107 (69)
400 10 0.071 (0.07) 7 (4-10) 90 (72)
Once every 2 weeks, mg
600 3 0.0425 (0.01) 8 (4-10) 27 (18)
700 13 0.041 (0.02) 8 (4-24) 83 (82)
800 7 0.033 (0.02) 8 (6-10) 126 (79)
Once per day 4 on/2 off schedule, mg
50 0.004 5 80-110
NOTE. Mean pharmacokinetic parameters after first dose of sunitinib.
Abbreviations: Cmax, peak plasma concentration; SD, standard deviation; T1/2, elimination half-life; Tmax, time to maximum plasma concentration.
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